Novartis to Open Data on Newly Approved Medicines to Researchers
This article is for subscribers only.
Novartis AG will join companies such as GlaxoSmithKline Plc in allowing researchers access to clinical trial data, as regulators demand more transparency.
Researchers will be able to request information on medicines that were newly approved in the U.S. and the European Union via an Internet portal, Basel, Switzerland-based Novartis said in an e-mailed statement today.